Literature DB >> 33520723

Telomere Dysfunction in Chronic Lymphocytic Leukemia.

Billy Michael Chelliah Jebaraj1, Stephan Stilgenbauer1,2.   

Abstract

Telomeres are nucleprotein structures that cap the chromosomal ends, conferring genomic stability. Alterations in telomere maintenance and function are associated with tumorigenesis. In chronic lymphocytic leukemia (CLL), telomere length is an independent prognostic factor and short telomeres are associated with adverse outcome. Though telomere length associations have been suggested to be only a passive reflection of the cell's replication history, here, based on published findings, we suggest a more dynamic role of telomere dysfunction in shaping the disease course. Different members of the shelterin complex, which form the telomere structure have deregulated expression and POT1 is recurrently mutated in about 3.5% of CLL. In addition, cases with short telomeres have higher telomerase (TERT) expression and activity. TERT activation and shelterin deregulation thus may be pivotal in maintaining the minimal telomere length necessary to sustain survival and proliferation of CLL cells. On the other hand, activation of DNA damage response and repair signaling at dysfunctional telomeres coupled with checkpoint deregulation, leads to terminal fusions and genomic complexity. In summary, multiple components of the telomere system are affected and they play an important role in CLL pathogenesis, progression, and clonal evolution. However, processes leading to shelterin deregulation as well as cell intrinsic and microenvironmental factors underlying TERT activation are poorly understood. The present review comprehensively summarizes the complex interplay of telomere dysfunction in CLL and underline the mechanisms that are yet to be deciphered.
Copyright © 2021 Jebaraj and Stilgenbauer.

Entities:  

Keywords:  chronic lymphocytic leukemia; clonal evolution; genomic complexity; prognostic factor; telomerase activation; telomere dysfunction

Year:  2021        PMID: 33520723      PMCID: PMC7844343          DOI: 10.3389/fonc.2020.612665

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  5 in total

Review 1.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

2.  Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Disease Biology and Signaling.

Authors:  Jérôme Paggetti; Martina Seiffert; Etienne Moussay
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 3.  Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability.

Authors:  Kristyna Zavacka; Karla Plevova
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

4.  Telomerase (hTERT) Overexpression Reveals a Promising Prognostic Biomarker and Therapeutical Target in Different Clinical Subtypes of Pediatric Acute Lymphoblastic Leukaemia.

Authors:  Beatriz Maria Dias Nogueira; Laudreísa da Costa Pantoja; Emerson Lucena da Silva; Fernando Augusto Rodrigues Mello Júnior; Eliel Barbosa Teixeira; Alayde Vieira Wanderley; Jersey Heitor da Silva Maués; Manoel Odorico de Moraes Filho; Maria Elisabete Amaral de Moraes; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Genes (Basel)       Date:  2021-10-17       Impact factor: 4.096

5.  Transcriptomic Analysis of Conserved Telomere Maintenance Component 1 (CTC1) and Its Association with Leukemia.

Authors:  Saadiya Zia; Netasha Khan; Komal Tehreem; Nazia Rehman; Rokayya Sami; Roua S Baty; Faris J Tayeb; Majed N Almashjary; Nouf H Alsubhi; Ghadeer I Alrefaei; Ramla Shahid
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.